Background: Consensus statements have recommended against the use of direct oral
anticoagulants (DOACs) in venous thromboembolism (VTE) for patients≥ 120 kg and≥ 40 …

Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients
of extreme weights are limited, however, they are still being prescribed in these populations …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

Background: Obesity is a well-known risk factor for venous thromboembolism (VTE),
however, obese patients are under-represented in clinical trials (1; 2). Four direct oral …

Abstract Background Direct oral anticoagulants (DOACs) are recommended in preference to
traditional anticoagulants (LMWH±warfarin) for treating acute venous thromboembolism …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Methods We utilized the Health Facts Center National Data Warehouse (Cerner) to perform
a retrospective analysis of patients with VTE (acute deep venous thrombosis (DVT) or …

The evidence of direct oral anticoagulants (DOACs) usage for venous thromboembolism
(VTE) in patients at extremes of body weight or mass index is limited. In such situations …

Background Randomized clinical trials comparing the efficacy and safety of direct oral
anticoagulants (DOAC) with vitamin K antagonist (VKA) or low molecular weight heparin …